Health Condition 1: C23- Malignant neoplasm of gallbladder
Conditions
Interventions
Intervention1: CRS and HIPEC: cytoreductive surgery( radical cholecystectomy, peritonectomy and adjacent organ resection if required) with HIPEC using Gemcitabine
Control Intervention1: NA: NA
Sponsors
Rajiv Gandhi Cancer Institute and research centre
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age : 18-65 years 2. ECOG : 0-1 3. All patients of gall bladder carcinoma with synchronous isolated peritoneal metastases 4. PCI
Exclusion criteria
Exclusion criteria: 1. Poor performance status(ECOG 2 and above) 2. Liver , lung, left paraaortic or other distant metastases excluding IAC lymph node metastases 3. Recurrent Disease 4. Locally unresectable disease 5. Requirement of major hepatectomy or HPD for R0 resection 6. Rare histology - NEC, sarcoma. 7. Significant medical comorbidity ââ?¬â?? Contraindication to chemotherapy 8. Progressive or stable disease on neoadjuvant CT 9. CKD 10. CLD 11. Not giving consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CRS and HIPEC may improve diseases free and overall survival in patients with ca GB and peritoneal metastasesTimepoint: status of the patient will be assessed every 3 months after surgery for disease recurrence or death . | — |
Secondary
| Measure | Time frame |
|---|---|
| Complication rate of CRS and HIPECTimepoint: Post operative period upto 30 days | — |
Countries
India
Contacts
Public ContactDr Shivendra Singh
Rajiv Gandhi Cancer Institute and research centre
Outcome results
None listed